Metastatic castration-resistant prostate cancer (mCRPC) is associated with poor prognosis. Currently, treatment selection and response assessment in mCRPC still rely largely on prostate-specific ...

Clear Cell Renal cell carcinoma (ccRCC) is the most common form of kidney cancer. The VHL tumor suppressor is lost or mutated in the majority of ccRCC and hereditary mutations in VHL predispose ...

Alicia Morgans outlines anemia management in the TALAPRO-3 regimen. The trial added talazoparib to enzalutamide in HRR-mutated metastatic hormone-sensitive prostate cancer, achieving 52% rPFS risk ...

Shilpa Gupta reports 3.5-year follow-up data from EV-302. Among all patients, 44% remained alive, double the chemotherapy arm, and more than 70% of complete responders were still alive. Complete ...

Kim Chi describes KLK2-comPAS, a trial investigating pasritamig, a bispecific IgG1 antibody that binds KLK2 and CD3. Phase one and two data in heavily pretreated patients showed radiographic ...

Comparative Analysis of Genitourinary Toxicity Following Bladder Outlet Obstruction Procedures in Patients Before Versus After Radiotherapy for Localized Prostate Cancer: A Retrospective Cohort Study ...

Development of a Risk Predictive Model for Erectile Dysfunction at 12 Months after COVID-19 Recovery: A Prospective Observational Study - Beyond the Abstract ...

Transdermal Application of H100 Gel to the Penile Shaft in Patients with Peyronie's Disease Infiltrates the Tunica Albuginea - Beyond the Abstract ...

Management of Asymptomatic Bacteriuria and Urinary Tract Infections in Patients with Neurogenic Bladder and Factors Associated with Inappropriate Diagnosis and Treatment - Beyond the Abstract ...

(UroToday.com) The 2026 Advanced Prostate Cancer Consensus Conference (APCCC) meeting featured a poster session and a presentation by David Fisher discussing a STOPCAP meta-analysis of individual ...

(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured a surgical and non-surgical treatment of non-muscle invasive bladder cancer session and a presentation by Dr.

(UroToday.com) The 2023 ASCO annual meeting included a kidney cancer session, featuring a presentation by Dr. Thomas Hutson discussing the final prespecified overall survival analysis of CLEAR, the ...